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Abstract: Myotonic dystrophy and fragile X syndrome are two genetically determined relatively common dis-
abilities. Both are examples of a new type of mutation mechanism called unstable or dynamic mutations, triple 
repeats expansions or DNA amplification. Fragile X syndrome is recognized as the main cause of hereditary 
mental retardation and myotonic dystrophy is considered the most common muscular dystrophy of adults. This 
is a prospective non randomized study of clinically affected people, in order to confirm the diagnosis with 
molecular techniques (Southern blot and PCR) and to perform cascade screening of the rest of the family to offer 
them adequate genetic counseling. We were able to corroborate the initial diagnosis in most clinical eases of 
myotonic dystrophy, but in the cases of mental retardation more than half studies were negative for fragile X 
syndrome, stressing the difficulties encountered by medical practitioners to diagnose this syndrome. The reasons 
for this are several; probable the main culprit is the subtle and unspecific clinical picture affected individuals 
exhibit, particularly children before puberty. Cascade screening, genetic counseling and selective abortion arc 
the only tools available to prevent these disabling diseases for the moment. Rev. Biol. Trop. 52(3): 501-505. 
Epub 2004 Dic 15. 
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Unstable mutations are responsible for an 
increasing number of genetic neurological dis-
eases since 1991 (Cuenca and Morales 1999). 
This recently discovered kind of mutation aris-
es when three adjacent nucleotides are repeat-
ed in tandem in numbers greater than normal 
and thus alter the actual gene function, their 
RNAs or proteic products, and consequently 
cause neurological or systemic disorders. 
Diseases of this origin and of higher preva-
lence are fragile X syndrome (FRAXA) - the 
main cause of hereditary mental retardation, 
affecting approximately 6% of severely men-
tally retarded persons, predominantly males 
(Castro 1998) - and myotonic dystrophy type 1  
(DM1) - the most common muscular dystro-
phy of the adult (Harper 1998). The molecular 
defect underlying DM is the expansion of an 
unstable (CTG)n trinucleotide repeat in the 3' 
untranslated region of a protein kinase gene, 
DMPK, on chromosome 19q13.3 (Buxton et 
al. 1992). In DM 1, unaffected people have 
from 5 to 37 repeats, but affected people have 
from 50 to several thousands repeats. The 
genetic basis for FRAXA was revealed by 
positional cloning in 1991 and resulted in an 
expansion of the triplet CGG in the 5' untrans-
lated region in the FMR1 gene (fragile X men-
tal retardation-1) localized near the distal 
boundary of Xq27.3 (Kremer et al. 1991). In 
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FRAXA, unaffected people have from 7 to 59 
repeats, patients with premutation have from 
60 to 230 repeats and affected patients (with 
the full mutation) have more that 230 repeats. 
Both diseases are disabling and have 
anticipation in common, meaning increasing 
severity of disabilities in subsequent genera-
tions in FRAXA, and both increasing severity 
and earlier age of onset in the case of muscular 
dystrophy type 1 (Morales et aL 2001, Cuenca 
et al. 2002). Both diseases segregate as domi-
nants and thus many affected persons are 
found in these families. Treatment for DNA 
amplification diseases is far from reach, and 
the only way to avoid occurrence or recurrence 
in the families is through contraception or pre-
natal diagnosis and selective abortion. In either 
case, prevention of disease can be achieved if 
adequate genetic counseling is given at the 
right time to at risk members. A prerequisite 
for genetic counseling is the precise diagnosis 
of the molecular status of unaffected but carri-
er family members. It is for this reason we 
have the objective to perform molecular diag-
nosis of these unstable mutations, not only to 
confirm the clinical impression, but to investi-
gate as many family members as possible to 
offer them the adequate genetic counseling that 
will enable them to choose the best reproduc-
tive option they can have. 
MATERIALS AND METHODS 
This is a prospective non randomized 
study of clinically affected people, in order to 
confirm the diagnosis with molecular tech-
niques and to perform cascade screening of the 
rest of the family to offer them adequate genet-
ic counseling. In the mental retardation cases 
the category of the FMR1 alleles (normal, pre-
mutation or full mutation) is assessed as well 
as the number of CGG repeats in premutation 
carriers and the methylation status of the 5' 
UTR of the gene. Southern blot was performed 
using probe StB12.3, restriction enzymes Hind 
III or EcoRI and EagI to determine methyla-
tion status, according to Rousseau et al.  
(1991). Normal bands are of 5.2 or 2.8Kb and 
5.2Kb respectively (Fig. 1). PCR was used to 
refine the diagnosis and performed according 
to Chong et al. (1994). In cases of clinical sus-
picion of myotonic dystrophy type 1, the pro-
tocol implies quantification of the number of 
CTG repeats at the 3' non coding end of the 
DMPK gene. This was performed following 
procedures of Shelbourne et a/. (1992) 
(Fig. 2). Genetic counseling was performed 
according to international standards, with 
plenty of educational materials and taking into 
account the socioeconomic and cultural status 
of the patients. 
Fig. 1. Autorradiography of DNA samples of FRAXA 
patients and relatives. DNA was digested with Hind III and 
hybridized with the gene probe Sth 12.3. Lines 3, 5 and 6 
show normal fragments. Line 4 shows a fragment of 5.4 
Kb, which represents a 200 bp expansion or approximate-
ly 66 repeats. Lines I and 2 show fragments of 5.5 and 5.6 
Kb, which represent an amplification of 100 and 130 
repeats respectively. 
Fig. 2. Autorradiography of DNA samples of DM1 
patients and relatives. DNA was digested with EcoRl and 
hybridized with the gene probe p5131.4. Line 1 is homozy-
gous for the normal fragment of 9.8 Kb and line 7 is 
homozygous for the normal fragment of 8.6 Kb. Line 2 is 
heterozygous for these two bands. The other lines show 
the expansion on the DMPK gene. Line 3 shows and 
expansion of 11 Kb, which represents 400 repeats. Lines 
4, 5 and 6 show an expansion of 1400, 170 and 730 
repeats respectively. 
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RESULTS 
For fragile X syndrome 93 index cases of 
mental retardation and relatives were studied, 
distributed as follows: (I) From 1I families 
(more than two related persons), 71 individuals 
were studied. In five families the unstable 
mutation was confirmed, with 15 individuals 
with mental retardation and full mutation, 
another 15 individuals had the premutation and 
so were normal carriers, and 16 had normal 
amount of repeats. In six families 25 individu-
als were studied and proved to have normal 
alleles. One of these families came to us with 
cytogenetic diagnosis of fragile X syndrome in 
the four mentally retarded offspring. (2) In two 
brother-brother pairs, one pair of first cousins 
and another mother-son duo, all eight individ-
uals resulted with normal alleles. (3) Finally, in 
14 mentally retarded children referred for 
molecular study, only one girl resulted with a 
full mutation. 
For muscular dystrophy cases, 126 molec-
ular diagnoses were performed as follows: (1) 
We studied 104 individuals from 18 families. 
In four families with 27 index cases and rela-
tives studied, myotonic dystrophy diagnosis 
was discarded since all alleles were normal. In 
14 families 77 individuals were studied and the 
results are shown in table 1. (2) In six pairs of 
individuals, one sister-sister, two mother-
daughter and three mother-son, we found the 
mutation in three pairs. In this group there are 
two cases of pediatric onset, one case of clas-
sical presentation, another case of Steinert's  
disease (congenital onset) and two individuals 
free of mutation. (3) Ten clinical cases of 
myotonic dystrophy were studied and eight 
proved positive with the classical manifesta-
tion of the disease and two resulted with nor-
mal alleles. 
DISCUSSION 
These results highlight the different pre-
dictive value of clinical diagnosis in these two 
diseases in the three subgroups studied, much 
higher for myotonic dystrophy and not so good 
for fragile X syndrome. The former disease is 
often referred to the neurologist, specially the 
most affected cases, and the signs and symp-
toms are highly suggestive of the correct diag-
nosis, when a good quality electromyography 
and physical test is performed. However, the 
DM phenotype is often misleading, and differ-
ential diagnosis is sometimes hard work for the 
physicians, due to the similarity with other 
myotonic conditions, and sometimes some 
patients are misdiagnosed as DM1. The accu-
rate diagnosis however, can be achieved only 
at the molecular level. A clinical diagnosis of 
DM1 but negative at the molecular level could 
indicate the presence of other myotonic condi-
tions, such as: DM2 or Cl- or Na+ chan-
nelopathies. For fragile X syndrome, on the 
contrary, the clinical picture is highly unspecific, 
particularly in prepuberal children and most of 
them are classified as cases of mental retarda-
tion of unknown origin. This is true not only in 
TABLE 1 
Molecular diagnosis of index cases with clinical impression of myotonic dystrophy and some of their close relatives 
N Number of triplet repeats, range 
62 5-37 
5 70-130 
4 70-100 
34 130-1630 
6 630-1050 
4 1070-1900 
II 5-37 
126 
Clinical manifestations of myotonic dystrophy 
Unaffected 
Asymptomatic 
Mild 
Classical 
Pediatric 
Congenital 
Clinically similar to myotonic dystrophy 
Total 
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Costa Rica, but in more developed countries as 
well. Moreover, of mental retardation cases 
showing X linkage, fragile X syndrome 
accounts for no more than half of them. This is 
a relatively new disease for most medical prac-
titioners, the clinical picture besides from 
being subtle is blurred for most of them and so 
they either ignore the disease or refer all cases 
of mental retardation for molecular study. 
Even cytogenetic diagnosis of index cases can 
be misleading and false negative or false posi-
tive results are not rare, on the contrary, false 
negatives arise from faulty lymphocyte culture 
methods and false positives from common 
fragile sites near the rare one associated with 
fragile X syndrome at Xq27.3. This last situa-
tion might explain the family with four men-
tally retarded children which where positive on 
cytogenetic grounds but we found negative at 
the molecular, more accurate level. 
Furthermore, we studied these children for 
FRAXE mental retardation and were negative 
as well. Cytogenetic diagnosis is less accurate 
and time consuming, and so we have aban-
doned this method in favor of molecular stud-
ies in index cases and relatives, but fifteen 
years ago it was the only test we had and 
allowed us to report a 6% prevalence of fragile 
X syndrome in a population of mentally retard-
ed children attending a special education 
school (Castro and Cuenca 1987, 1996). 
According to the practical experience of at 
least four studies that have attempted cascade 
screening for fragile X syndrome, it has proved 
to be feasible and useful. Follow up of the 
screened positive families has evidenced a 
marked reduction in the birth of affected chil-
dren through contraception and prenatal diag-
nosis (Murray et al. 1997). 
In both genetic diseases studied, the accu-
rate diagnosis of the unstable mutation associ-
ated to each of them allowed unambiguous 
detection of clinically affected individuals and 
of healthy carriers. In this way, we were able to 
demonstrate an erroneous clinical or cytoge-
netic diagnosis in several disabled individuals,  
who consequently had to be studied for other 
etiology for their diseases. Even more important 
was the detection of healthy carrier individuals 
at high risk for disabled offspring. These people 
received genetic counseling in order to help 
them take the best reproductive options accord-
ing to their own risk and harm perceptions, 
moral and religious beliefs, economic capabili-
ty to afford the expense of rehabilitation of 
affected family members and other issues. 
We consider of utmost importance to per-
form molecular diagnosis in cases with clinical 
impression of disability associated to unstable 
mutations in genes FMR1 and DMPK in Costa 
Rica. To increase the level of suspicion in 
medical practitioners it is necessary for them 
to acknowledge the constant need to keep in 
pace with genetic advances, particularly of 
these two relatively common diseases. 
The correct identification of index cases 
allows cascade screening which in turn 
enables adequate genetic counseling to the 
families at risk and the possibility of preven-
tion of these diseases in Costa Rica. Since 
these disabilities pose a considerable burden 
to the caretakers in particular and to society in 
general, our health authorities must support 
and finance our molecular genetic projects on 
behalf of our population. 
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RESUMEN 
La distrofia miotanica tipol (DM1) y el sindrome del 
cromosoma X fragil (FRAXA) son dos enfermedades he-
rcditarias relativamente comunes. Ambas constituyen 
ejemplos de un nuevo tipo de mecanismo mutational, lla-
mado mutaciones inestables o dinamicas, expansion de tri-
pietas, a amplificacien del ADN. La DM1 se considera 
como la distrofia muscular mss frecucnte en los adultos y 
FRAXA es la principal cause de retardo mental heredita-
rio. Este trabajo presents resultados actualizados de un es-
tudio prospectivo no aleatorio en pacientes clinicamente 
afectados, quo se realize con el objetivo de confirmar el 
diagnostico con tecnicas moleculares (Hibridacion dc Sout-
hern y reaction en cadena de la polimerasa, PCR), y !lever 
a cabo el tamizaje en cascade del resto de la familia para 
ofrecerles consejo genetico adecuado. Se confirm!, el diag-
nastier) clinico inieial en la mayoria de los casos do distro-
fia miotenica, porn en los casos con retardo mental, mss de 
la mitad de los anal isis resultaron negativos pare la amplifi-
eacion en el gen FMR1, especifica de FRAXA. La razon 
principal para esto podria ser el cuadro clinico muy sutil que 
muestran los nifios afoctados antes do Ia pubertad. Los (mi-
cas metodos disponibles pars prevenir estas discapacidades 
por el momento son, el tamizaje en cascade, el consejo ge-
netic° y el aborto selectivo. De los cuales, el Oltitno no se 
puedc [lever a cabo segAn las leyes vigentes en Costa Rica. 
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